Deleveraging-Driven Value in a Post-Patent-Cliff Specialty Pharma

Bausch Health Companies Inc. (BHC) is a global diversified pharmaceutical company headquartered in Laval, Quebec. It operates through two reportable segments:

• Bausch + Lomb (majority-owned, separately listed as BLCO): Vision care (contact lenses, lens care), surgical (cataract, vitreous), and ophthalmic pharmaceuticals. This is the growth and multiple-expansion asset, and BHC retains roughly 88% ownership.
• Bausch Health (the "remainder"): Primarily Salix Pharmaceuticals (GI), plus international pharmaceuticals, Solta Medical (aesthetics devices), and legacy diversified brands.

How it makes money: BHC monetizes branded prescription and OTC products through wholesale distributors, pharmacies, and hospitals, with a meaningful international footprint. Revenue is concentrated in a handful of large brands — Xifaxan is the single largest contributor — supplemented by a long tail of mature products.

Customers: Primarily wholesalers (McKesson, Cardinal Health, AmerisourceBergen in the U.S.), retail pharmacy chains, hospitals, and, for BLCO, optical retailers and surgical centers globally.

Scale: Consolidated revenue runs in the ~$9.5B range, with BLCO contributing roughly $4.5B+ and the remainder (led by Salix) contributing the balance. The company employs tens of thousands globally and carries a debt load that dwarfs its equity market capitalization.

Near-term (next 12–24 months):

• Xifaxan defense and label expansion: Any positive litigation or IP outcome, or expansion into adjacent indications (e.g., hepatic encephalopathy recurrence), stabilizes the largest cash contributor.
• BLCO stake monetization: Further sell-downs or structured transactions convert a non-cash asset into debt reduction.
• Salix volume growth: Trulance and Plenvu continue to build, partially offsetting mature-brand erosion.
• Cost discipline: Ongoing restructuring and SG&A leverage support margin.

Medium-term (3–5 years):

• Full separation of Bausch + Lomb: The endgame is a clean split, leaving a leaner Salix-centric entity and unlocking the vision-care multiple for shareholders.
• Debt maturity wall management: Refinancing at lower rates (if achievable) and continued amortization reduce interest burden.
• Aesthetics/Solta divestiture: A sale would provide a discrete deleveraging event.
• Pipeline contribution: Ophthalmic and GI pipeline assets, if approved, add incremental revenue, though they are not the core of the thesis.

Note: Historical figures are illustrative of the company's trajectory; GAAP EPS of -$2.95 reflects amortization, impairment, and interest costs that adjusted figures exclude.

The narrative is straightforward: revenue is roughly flat-to-modestly-growing, margins are stable, and the entire equity story is the ~$1.0B–$1.4B annual gap between adjusted EBITDA and interest expense plus capex. That gap is the deleveraging fuel. GAAP losses persist because of non-cash amortization and the sheer weight of interest, but adjusted cash generation is what retires debt. Each $1B of net debt reduction removes roughly $70–$90M of annual interest, compounding the equity's residual value.

Market size / TAM: The global pharmaceuticals market exceeds $1.5 trillion, with the GI and ophthalmology sub-segments representing tens of billions annually. BHC competes in branded specialty pharma (GI, dermatology, ophthalmology) and vision care, both large, growing, and increasingly competitive.

Competitive positioning: BHC's moat rests on (1) Xifaxan's clinical entrenchment in GI, (2) BLCO's global vision-care brand and distribution, and (3) a broad, if aging, product portfolio. Its weakness is leverage and patent concentration.

Named comparables:

• Bausch + Lomb (BLCO): The directly comparable vision-care asset; its multiple is the reference for BHC's stake value.
• Teva Pharmaceutical (TEVA): Levered specialty/generic peer with a similar deleveraging narrative.
• Organon (OGN): Spun-off women's health/diversified pharma with comparable leverage dynamics.
• Perrigo (PRGO): Consumer/OTC pharma peer with margin and leverage parallels.
• AbbVie (ABBV): Larger specialty pharma with a GI franchise (Skyrizi/Rinvoq), illustrating the premium a clean balance sheet commands.

DCF discussion: A sum-of-the-parts approach is more informative than a consolidated DCF. Discounting BHC's share of BLCO's cash flows and marking the stake to market, then valuing the Salix/remainder cash flows net of the debt stack, produces an equity value materially above $2.3B in a base case. Key DCF inputs: WACC in the 7–9% range (reflecting high leverage but low beta of 0.37), terminal growth of 1–2%, and a Xifaxan exclusivity assumption that dominates the terminal value. Sensitivity to the Xifaxan loss date is extreme — moving it two years changes equity value by a large multiple of the current market cap.

Comparable multiples (illustrative):

BHC trades at a steep discount to peers on EV/EBITDA, reflecting its leverage and patent risk. The discount is the opportunity — and the risk.

• Xifaxan exclusivity loss: The single largest risk. An adverse IPR or generic entry before 2028 removes a disproportionate share of EBITDA and could impair the deleveraging path.
• Refinancing and interest-rate risk: With a debt stack in the high single-digit billions, any inability to refinance maturities on reasonable terms threatens the entire equity thesis.
• BLCO stake value volatility: A decline in BLCO's share price directly reduces the value of BHC's largest asset and the credibility of the sum-of-the-parts story.
• Regulatory and pricing pressure: U.S. drug pricing reform, international reference pricing, and generic competition pressure revenue across the portfolio.
• Litigation and contingent liabilities: Beyond Xifaxan, legacy litigation and product-liability matters create tail risk to cash flows.
• Execution risk on separation: A failed or delayed BLCO separation leaves the conglomerate discount intact.